The development of drug delivery systems took place just a few decades ago, and its evolution has brought about considerable therapeutic and economic impact. The progress from preformed implants to in situ forming implants has opened new avenues of possibilities to the patients and the healthcare providers. Procedures there were once not convenient and exposed patients with possible complications can be done nowadays by the patients through a syringe in the safety of their home. The products on the market have aided the patients to combat difficult health conditions so far and will still play an important role in the future. Nevertheless, the continuation of science and technology allow us to look for further improved products. In this regard, an implant that can cause minimal damage to the patients and put them at least risk is not available yet. However, with the progress being made, this will not take a long time until it becomes a reality. The work with nanoparticles made of PGA has been covered before in our research group and others. Further study in our group has dealt with new possibilities to work with poly(glycerol adipate) as a drug conjugate.